SCOTTSDALE, AZ / ACCESSWIRE / April 27, 2020 / CBD Life Sciences Inc. (OTC PINK:CBDL) through its wholly owned subsidiary “LBC Bioscience Inc.” is pleased to announce that our “PROPRIETARY 100 MG PURE CBD TABLETS” has finally arrived to our Facility and is ready to be shipped out to consumers. The product consists of 100 MG CBD tablets 10 count in each container. This extraordinary product can help consumers relive pain, ease muscle soreness, inflammation, tension and more. Consumers can place their order today on our website www.lbcbioscienceinc.com. CBD (Cannabidiol) has shown promising indication for the health & wellness industry and has become increasingly widespread throughout the public.
Lisa Nelson, CEO of CBD Life Sciences, Inc. commented “We are pleased to announce that our new CBD Tablet is available to the public for purchase. The tablets arrived at our facility over the weekend and we are eager for our consumers to try our latest product. We thank you for your patience and hope you enjoy the CBD Tablets! Lisa Nelson continued “We will continue to update the public about new product releases, trade shows, events and any updated information regarding LBC Bioscience Inc.”
About CBD Life Sciences Inc.
CBD Life Sciences Inc. is a publicly traded company having its common shares quoted on the OTC Markets under the symbol ‘CBDL’. The Company’s primary focus is to identify, evaluate and acquire undervalued opportunities with the objective of increasing shareholder value. The acquisition of LBC Bioscience Inc. is the first in the CBD space and the Company is actively pursuing for additional opportunities within this emerging sector.
About LBC Bioscience Inc.
LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC has developed and is retailing/wholesaling a full line of cannabidiol based organic products including: CBD Hemp Drops, CBD Pain Relief Creams, CBD Anxiety & Sleep Supplements, CBD Gummy’s, CBD Brain Booster Coffee, CBD Weight Loss Coffee, CBD Skincare Line, CBD Pet Treats, CBD Pet Drops, CBD Cat Treats and CBD Tablets. LBC Bioscience Inc.’s products can be viewed and purchased on the Company’s website at www.lbcbioscienceinc.com
Contact Information Investor Relations
Ten Associates LLC 11529 N. 120th St.
Contact: Thomas E. Nelson
Scottsdale, Arizona 85259 USA
Contact: Thomas E. Nelson
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc’s, Inc.’s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: CBD Life Sciences Inc.
View source version on accesswire.com: